Marc Suárez-Calvet, MD, PhD, Barcelonaβeta Brain Research Center (BBRC), Barcelona, Spain, discusses the future of Alzheimer’s disease (AD) biomarker research. The next steps involve working towards the implementation of plasma biomarkers and aiming to study more diverse populations, in order to determine if these blood biomarkers are efficacious in the real world. Currently, there are well validated diagnostic tools for AD, therefore research should focus on developing biomarkers for purposes other than diagnostics, such as prognostication. Furthermore, there are other dementia-causing neurological diseases which currently lack effective biomarkers, for example frontotemporal dementia and Lewy body disease. Thus, the next challenge is to focus on developing biomarkers for a wider range of neurodegenerative diseases. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
